Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 study in collaboration with the Mortalité 2005 survey, ANRS EN19).
BACKGROUND
More than 10 years after the introduction of combination antiretroviral therapy (cART), we examined the trend in the proportion of deaths caused by end-stage liver disease (ESLD) in HIV-infected adults in France between 1995 and 2005.


METHODS
In 2005, 34 departments prospectively recorded all deaths in HIV-infected patients who were followed in those departments (around 24 000).


RESULTS
were compared with those of four previous cross-sectional surveys conducted since 1995 using the same methodology. Results Among 287 reported deaths in 2005, 100 (35%) were related to AIDS, and 48 (17%) to ESLD. Three out of four patients who died from ESLD-related causes had chronic hepatitis C. Excessive alcohol consumption was reported in approximately half of the patients (48%). At death, 62% of patients had undetectable HIV viral load and the median CD4 count was 237 cells/microL. From 1995 to 2005, the proportion of deaths caused by ESLD increased from 2 to 17% (P<0.001). The proportion of deaths caused by hepatocellular carcinoma increased from 5% in 1995 to 25% in 2005 (P=0.0337).


CONCLUSIONS
Over the 10 years from 1995 to 2005, the proportion of deaths caused by hepatitis C virus-related ESLD has increased in HIV-infected patients. ESLD is currently a leading cause of death in this population, with hepatocellular carcinoma representing a quarter of liver-related deaths. Recommendations for the detection of hepatocellular carcinoma should be strictly applied in these patients.
Rosenthal
E
E
Department of Internal Medicine, Archet Hospital Centre, University of Nice-Sophia Antipolis, Nice, France. rosenthal.e@chu-nice.fr
Salmon-Céron
D
D
Lewden
C
C
Bouteloup
V
V
Pialoux
G
G
Bonnet
F
F
Karmochkine
M
M
May
T
T
François
M
M
Burty
C
C
Jougla
E
E
Costagliola
D
D
Morlat
P
P
Chêne
G
G
Cacoub
P
P
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000401:mortality; D000328:Adult; D000368:Aged; D000428:Alcohol Drinking / Q000401:mortality; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D006528:Carcinoma, Hepatocellular / Q000150:complications / Q000401:mortality*; D002423:Cause of Death / Q000639:trends; D003430:Cross-Sectional Studies; D005260:Female; D005602:France / Q000453:epidemiology; D015658:HIV Infections / Q000150:complications / Q000401:mortality*; D019698:Hepatitis C, Chronic / Q000150:complications / Q000401:mortality*; D006801:Humans; D008104:Liver Cirrhosis, Alcoholic / Q000150:complications / Q000401:mortality; D008113:Liver Neoplasms / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000509:alpha-Fetoproteins / Q000032:analysis
D000509:alpha-Fetoproteins